Zoetis Inc. (ZTS) Holdings Lifted by Zurcher Kantonalbank Zurich Cantonalbank
Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 6.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 103,442 shares of the company’s stock after acquiring an additional 5,954 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Zoetis were worth $6,595,000 as of its most recent SEC filing.
A number of other institutional investors also recently added to or reduced their stakes in ZTS. BlackRock Inc. increased its stake in shares of Zoetis by 3.9% in the second quarter. BlackRock Inc. now owns 37,495,299 shares of the company’s stock valued at $2,338,957,000 after buying an additional 1,412,829 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Zoetis by 2.8% in the second quarter. Vanguard Group Inc. now owns 33,654,686 shares of the company’s stock valued at $2,099,379,000 after buying an additional 910,265 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of Zoetis by 55.4% in the second quarter. Alliancebernstein L.P. now owns 10,370,388 shares of the company’s stock valued at $646,905,000 after buying an additional 3,695,449 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Zoetis by 7.2% in the second quarter. American Century Companies Inc. now owns 6,207,974 shares of the company’s stock valued at $387,253,000 after buying an additional 417,455 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in Zoetis by 7,717.4% in the second quarter. Janus Henderson Group PLC now owns 5,809,086 shares of the company’s stock valued at $362,372,000 after acquiring an additional 5,734,776 shares during the last quarter. Hedge funds and other institutional investors own 93.37% of the company’s stock.
Several equities analysts recently issued reports on the company. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price target on the stock in a report on Thursday, October 12th. Cantor Fitzgerald reiterated a “buy” rating and issued a $75.00 price target on shares of Zoetis in a report on Wednesday, September 6th. BidaskClub cut Zoetis from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Morgan Stanley raised their price target on Zoetis from $61.00 to $70.00 and gave the company an “equal weight” rating in a report on Friday, November 3rd. Finally, Goldman Sachs Group Inc reiterated a “neutral” rating and issued a $62.00 price target on shares of Zoetis in a report on Monday, August 7th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Zoetis presently has a consensus rating of “Buy” and a consensus price target of $67.65.
Zoetis Inc. (ZTS) traded up $0.22 during trading hours on Monday, hitting $71.29. The stock had a trading volume of 1,200,200 shares, compared to its average volume of 2,790,426. Zoetis Inc. has a fifty-two week low of $48.55 and a fifty-two week high of $72.14. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95. The company has a market cap of $34,738.76, a PE ratio of 32.70, a PEG ratio of 2.10 and a beta of 1.02.
Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.02. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.32 billion. During the same quarter in the previous year, the business posted $0.52 EPS. Zoetis’s revenue for the quarter was up 8.5% on a year-over-year basis. equities analysts anticipate that Zoetis Inc. will post 2.37 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 9th will be given a $0.105 dividend. This represents a $0.42 dividend on an annualized basis and a yield of 0.59%. The ex-dividend date is Wednesday, November 8th. Zoetis’s dividend payout ratio is presently 22.11%.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.